WallStreetZenWallStreetZen

NASDAQ: GLPG
Galapagos Nv Stock

$25.75+0.12 (+0.47%)
Updated Jun 21, 2024
GLPG Price
$25.75
Fair Value Price
-$22.44
Market Cap
$1.70B
52 Week Low
$25.32
52 Week High
$44.25
P/E
N/A
P/B
0.55x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.51
Operating Cash Flow
N/A
Beta
0.76
Next Earnings
Aug 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

GLPG Overview

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GLPG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GLPG ($25.75) is overvalued by 214.75% relative to our estimate of its Fair Value price of -$22.44 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GLPG ($25.75) is not significantly undervalued (214.75%) relative to our estimate of its Fair Value price of -$22.44 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GLPG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more GLPG due diligence checks available for Premium users.

Be the first to know about important GLPG news, forecast changes, insider trades & much more!

GLPG News

Valuation

GLPG fair value

Fair Value of GLPG stock based on Discounted Cash Flow (DCF)
Price
$25.75
Fair Value
-$22.44
Undervalued by
214.75%
GLPG ($25.75) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GLPG ($25.75) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

GLPG price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0x
Industry
-5.75x
Market
30.75x

GLPG price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.55x
Industry
6.2x
GLPG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GLPG's financial health

Profit margin

Revenue
$67.9M
Net Income
$98.1M
Profit Margin
144.5%

Assets to liabilities

Assets
$4.7B
Liabilities
$1.6B
Debt to equity
0.51
GLPG's short-term assets ($4.07B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLPG's short-term assets ($4.07B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLPG's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GLPG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$146.4M
Investing
$32.2M
Financing
-$1.3M

GLPG vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
GLPG$1.70B+0.47%N/A0.55x
SNDX$1.70B+4.05%-6.21x3.46x
HRMY$1.71B+4.58%12.82x3.32x
KROS$1.68B+2.27%-9.02x3.69x
VCYT$1.72B+3.58%-24.24x1.54x

Galapagos Nv Stock FAQ

What is Galapagos Nv's quote symbol?

(NASDAQ: GLPG) Galapagos Nv trades on the NASDAQ under the ticker symbol GLPG. Galapagos Nv stock quotes can also be displayed as NASDAQ: GLPG.

If you're new to stock investing, here's how to buy Galapagos Nv stock.

What is the 52 week high and low for Galapagos Nv (NASDAQ: GLPG)?

(NASDAQ: GLPG) Galapagos Nv's 52-week high was $44.25, and its 52-week low was $25.32. It is currently -41.81% from its 52-week high and 1.72% from its 52-week low.

How much is Galapagos Nv stock worth today?

(NASDAQ: GLPG) Galapagos Nv currently has 65,897,071 outstanding shares. With Galapagos Nv stock trading at $25.75 per share, the total value of Galapagos Nv stock (market capitalization) is $1.70B.

Galapagos Nv stock was originally listed at a price of $50.50 in May 14, 2015. If you had invested in Galapagos Nv stock at $50.50, your return over the last 9 years would have been -49.01%, for an annualized return of -7.21% (not including any dividends or dividend reinvestments).

How much is Galapagos Nv's stock price per share?

(NASDAQ: GLPG) Galapagos Nv stock price per share is $25.75 today (as of Jun 21, 2024).

What is Galapagos Nv's Market Cap?

(NASDAQ: GLPG) Galapagos Nv's market cap is $1.70B, as of Jun 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Galapagos Nv's market cap is calculated by multiplying GLPG's current stock price of $25.75 by GLPG's total outstanding shares of 65,897,071.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.